 |
 |

Lymphokine Production and Lymphocyte Subpopulations in Patients With Head and Neck Squamous Carcinoma
Gregory T. Wolf, MD;
Edmund J. Lovett, III, PhD;
Karen A. Peterson;
Mark L. Beauchamp, MD;
Saan R. Baker, MD
Arch Otolaryngol. 1984;110(11):731-735.
Abstract
 |  |
Prior studies of impaired cellular immune reactivity in patients with head and neck squamous carcinoma (HNSC) suggest that immune deficiency associated with tumor growth may be related, in part, to alterations in immunoregulatory functions. To determine if production of soluble mediators of the immune response (lymphokines) is impaired in patients with HNSC, leukocyte migration inhibition in response to phytohemagglutinin was assessed in 32 patients with HNSC and 29 normal subjects and was correlated with levels of specific peripheral blood lymphocyte subpopulations to determine if quantitative levels of immunoregulatory lymphocyte subpopulations were related to in vitro lymphokine production. In the patients with cancer, leukocyte inhibitory factor production was consistently and significantly impaired and was directly related to levels of T4-positive (helper/inducer) lymphocytes. Substantial differences in levels of individual subpopulations were not detected among normal subjects and patients with cancer; however, the mean T4/T8 ratio was substantially increased in the patients with cancer. The findings confirm and extend prior observations of impaired cellular immune mechanisms in patients with HNSC and suggest that impaired lymphokine production may be related to quantitative and qualitative alterations in lymphocyte subpopulations.
(Arch Otolaryngol 1984;110:731-735)
Author Affiliations
From the Departments of Otolaryngology—Head and Neck Surgery (Drs Wolf, Beauchamp, and Baker) and Pathology (Dr Lovett), University of Michigan Hospitals, and the Research Service, Veterans Administration Medical Center (Ms Peterson), Ann Arbor, Mich.
Footnotes
Accepted for publication June 18, 1984.
Read before the American Society for Head and Neck Surgery, May 10, 1984.
Reprint requests to Department of Otolaryngology—Head and Neck Surgery, C6071 Outpatient Bldg, University Hospitals, Ann Arbor, MI 48109 (Dr Wolf).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Report of a Clinical Trial in 12 Patients With Head and Neck Cancer Treated Intratumorally and Peritumorally With Multikine
Feinmesser et al.
Arch Otolaryngol Head Neck Surg 2003;129:874-881.
ABSTRACT
| FULL TEXT
Phospholipid Metabolite Expression by Head and Neck Squamous Cell Carcinoma
Mann et al.
Arch Otolaryngol Head Neck Surg 1994;120:763-769.
ABSTRACT
Interleukins and Contrasuppression Induce Immune Regression of Head and Neck Cancer
Hadden et al.
Arch Otolaryngol Head Neck Surg 1994;120:395-403.
ABSTRACT
Oral Cancer
Gerson
CROBM 1990;1:153-166.
ABSTRACT
| FULL TEXT
Interleukin 2 Receptor Expression in Patients With Head and Neck Squamous Carcinoma: Effects of Thymosin {alpha}1 In Vitro
Wolf et al.
Arch Otolaryngol Head Neck Surg 1989;115:1345-1349.
ABSTRACT
Alterations in T-Lymphocyte Subpopulations in Patients With Head and Neck Cancer: Correlations With Prognosis
Wolf et al.
Arch Otolaryngol Head Neck Surg 1987;113:1200-1206.
ABSTRACT
T-Cell Subsets and Natural Killer Cell Function With Squamous Cell Carcinoma of the Head and Neck
Strome et al.
Arch Otolaryngol Head Neck Surg 1987;113:1090-1093.
ABSTRACT
Definite vs Adjuvant Radiotherapy: Comparative Effects on Lymphocyte Subpopulations in Patients With Head and Neck Squamous Carcinoma
Wolf et al.
Arch Otolaryngol Head Neck Surg 1985;111:716-726.
ABSTRACT
|